Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefepime

B A Cunha1, M V Gill

  • 1Infectious Disease Division, Winthrop-University Hospital, Mineola, New York, USA.

The Medical Clinics of North America
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Cefepime offers advantages over older cephalosporins due to its effectiveness against resistant bacteria and convenient dosing. It shows comparable efficacy to ceftazidime and retains activity against challenging organisms, making it a valuable antibiotic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Viral influenza-like illnesses: dynamic interrelationships during the 2015-2016 influenza season in hospitalized patients.

The Journal of hospital infection·2017
Same author

Editor's Mail.

Postgraduate medicine·2016
Same author

Are atypical lymphocytes present with viral influenza-like illnesses (ILIs) in hospitalized adults?

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2016
Same author

Problems+Solutions.

Postgraduate medicine·2016
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Third-generation cephalosporins face challenges from emerging resistant organisms producing extended-spectrum beta-lactamases.
  • Cefepime, a fourth-generation cephalosporin, presents enhanced activity and a favorable dosing schedule.

Purpose of the Study:

  • To evaluate the clinical efficacy and microbiological activity of cefepime.
  • To compare cefepime with ceftazidime in treating specific infections.
  • To assess cefepime's potential in combating resistant bacterial strains.

Main Methods:

  • Review of comparative and noncomparative clinical trials in the US and Europe.
  • Evaluation of in vitro activity against resistant organisms like Enterobacteriaceae and Pseudomonas aeruginosa.

Related Experiment Videos

  • Assessment of cross-resistance and resistance induction potential.

    • Main Results:

    • Cefepime demonstrated clinical efficacy in treating lower respiratory tract, urinary tract, and skin infections, including bacteremia.
    • It showed comparable clinical and bacteriologic response rates to ceftazidime in febrile neutropenic patients.
    • Cefepime maintained activity against cephalosporin-resistant E. cloacae and E. coli, and ceftazidime-resistant P. aeruginosa.

    Conclusions:

    • Cefepime offers advantages over older cephalosporins, including improved activity against resistant organisms and a convenient dosing schedule.
    • Its low cross-resistance and resistance induction potential make it a favorable alternative to ceftazidime.
    • Cefepime is a valuable therapeutic option for various infections, especially those caused by resistant bacteria.